Evolocumab

Drug Profile

Evolocumab

Alternative Names: AMG-145; Repatha

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Amgen Astellas BioPharma
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 05 Jun 2017 Amgen files sBLA for inclusion of cardiovascular outcomes data in the label for evolocumab in USA
  • 05 Jun 2017 Amgen files a variation to the marketing authorisation to the European Medicines Agency for inclusion of cardiovascular outcomes data in the label for evolocumab in European Union
  • 22 May 2017 Amgen initiates a phase III trial in Hypercholesterolemia in subjects with HIV infection (Adjunctive treatment) (NCT02833844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top